Atea Pharma (AVIR): Forward Price-to-Revenue Multiple

Corporate company logo of Atea Corp (AVIR)

Risks for Atea Pharmaceuticals (AVIR) are linked to potential clinical trial failures and a decline in demand for antiviral agents. This forward P/S chart illustrates the business valuation dynamics relative to expected revenues, where 1.50 expresses the latest metric level. Growth potential is based on RNA polymerase patents and oral medications, while liquidity and strict FDA requirements ensure the stability of its position.

ateapharma.com - AVIR Market Cap to Future Revenue Ratio (period 07/04/2022 - 03/05/2023)

Comprehensive metric breakdowns and analytics for Atea Corp (AVIR)

- current price and projected stock value:
Stock Price Atea Pharmaceuticals, Inc.|AVIR - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Valuation Atea Corp|AVIR - Aggregate Business Value
- business book valuation details:
Book Value per Share Atea Pharmaceuticals|AVIR - Total Stockholders' Equity|Market Capitalization to Book Value Ratio ateapharma.com|AVIR - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Atea Pharmaceuticals|AVIR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Atea Pharmaceuticals|AVIR - Company Aggregate Indebtedness|Debts to Book Capitalization Atea Corp|AVIR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Atea Pharmaceuticals|Quick Liquidity ateapharma.com
- financial results and valuation multiples details:
AVIR - Final Profit|Expected Profit Atea Pharmaceuticals|AVIR - Price to Earnings Ratio|Forward P/E Multiple Atea Pharmaceuticals Inc|AVIR - PEG Multiple|EV/EBITDA Multiple Atea Corp|AVIR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Atea Pharmaceuticals|AVIR - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ateapharma.com|AVIR - Earnings growth in current year|Expected earnings per share growth for next year Atea Pharmaceuticals
- revenue and sales details:
AVIR - Company Total Sales|Projected Sales Volume Atea Pharmaceuticals, Inc.|AVIR - Price-to-Revenue Coefficient|Forward P/S Multiple Atea Corp
Fundamental valuation:Atea Pharmaceuticals, Inc. AVIR
Manufactured products of Atea Pharmaceuticals

This indicator compares current market capitalization with expected sales volume, determining the degree of overpayment for future cash flows and separating market noise from the actual trend. For Atea Pharmaceuticals (AVIR), with its production outsourcing model and minimal environmental footprint, the forward P/S ratio trend allows for an assessment of the extent to which the market is willing to award a premium to the company's intellectual capital amid low operational overhead.

Key competitors

Forward P/S Multiple GILD (Gilead Sciences)|Forward P/S Multiple Cidara Therapeutics Corp CDTX|NVAX: Forward Price-to-Revenue Multiple|CureVac Pharma - Price to Expected Revenue Ratio|VALN: Forward P/S Multiple|Market Cap to Future Revenue Ratio vir.bio (VIR)|SIGA (SIGA Technologies) - Forward P/S Multiple|Forward P/S Multiple Emergent BioSolutions Inc|Forward Price-to-Revenue Multiple IVVD (Invivyd, Inc.)|ENTA (Enanta Pharmaceuticals, Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio Inovio Pharmaceuticals INO|HLVX (hillevax.com) - Future Price to Revenue|Kalaris Therapeutics - Forward P/S Multiple|Forward Price to Sales DYAI (Dyadic International)|NNVC: Forward P/S Multiple|Talphera Corporation (TLPH) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cocrystal Pharma, Inc.|TRAW: Forward Price to Sales|Price-to-Projected Revenue Ratio Dogwood Therapeutics, Inc. (DWTX)|Forward Price-to-Revenue Multiple Qualigen Therapeutics Inc QLGN|Forward P/S Multiple ALVR (AlloVir)|Forward P/S Multiple VBI Vaccines, Inc. VBIV|Virios - Forward P/S Multiple|Vaxart, Inc. (VXRT) - Forward Price-to-Revenue Multiple